222

ABL BIO

No trades
See on Supercharts
Market capitalization
‪1.03 T‬KRW
‪−2.65 B‬KRW
‪65.55 B‬KRW
‪30.81 M‬
Beta (1Y)
1.88

About ABL BIO

CEO
Sang-Hoon Lee
Headquarters
Seongnam-si
Website
Employees (FY)
102
Founded
2016
ISIN
KR7298380007
FIGI
BBG00MRY7S53
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company was founded by Lee Sang-Hoon on February 16, 2016 and is headquartered in Seongnam-si, South Korea.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 298380 is 22450 KRW — it has decreased by 1.10% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange ABL BIO stocks are traded under the ticker 298380.
298380 stock is 4.79% volatile and has beta coefficient of 1.88. Check out the list of the most volatile stocks — is ABL BIO there?
One year price forecast for ABL BIO has a max estimate of 37000 KRW and a min estimate of 36000 KRW.
Yes, you can track ABL BIO financials in yearly and quarterly reports right on TradingView.
298380 stock has risen by 1.13% compared to the previous week, the month change is a 14.80% fall, over the last year ABL BIO has showed a 1.97% decrease.
298380 net income for the last quarter is ‪−12.51 B‬ KRW, while the quarter before that showed ‪−4.11 B‬ KRW of net income which accounts for −204.51% change. Track more ABL BIO financial stats to get the full picture.
Today ABL BIO has the market capitalization of ‪1.03 T‬, it has decreased by 11.05% over the last week.
No, 298380 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 298380 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABL BIO stock right from TradingView charts — choose your broker and connect to your account.
298380 reached its all-time high on Aug 5, 2020 with the price of 40150 KRW, and its all-time low was 12250 KRW and was reached on Mar 19, 2020.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 102.00 employees. See our rating of the largest employees — is ABL BIO on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABL BIO technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABL BIO stock shows the buy signal. See more of ABL BIO technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ABL BIO future price: according to them, 298380 price has a max estimate of 37000.00 KRW and a min estimate of 36000.00 KRW. Read a more detailed ABL BIO forecast: see what analysts think of ABL BIO and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABL BIO EBITDA is ‪−27.32 M‬ KRW, and current EBITDA margin is −0.04%. See more stats in ABL BIO financial statements.